Edition:
United States

Jiangsu Hengrui Medicine Co Ltd (600276.SS)

600276.SS on Shanghai Stock Exchange

67.58CNY
15 Dec 2017
Change (% chg)

¥-2.06 (-2.96%)
Prev Close
¥69.64
Open
¥69.60
Day's High
¥69.60
Day's Low
¥67.49
Volume
10,817,990
Avg. Vol
11,022,206
52-wk High
¥76.92
52-wk Low
¥37.25

Chart for

About

JIANSU HENGRUI MEDICINE CO., LTD. is a China-based company, principally engaged in the manufacture and distribution of pharmaceutical tablets, injections and raw materials. The Company's main products portfolio consists of antineoplastic drugs, angiomyocardiac drugs, drugs for surgery, contrast agents, antibiotics, specialty... (more)

Overall

Beta: 0.48
Market Cap(Mil.): ¥190,280.50
Shares Outstanding(Mil.): 2,816.88
Dividend: 0.11
Yield (%): 0.17

Financials

  Industry Sector
P/E (TTM): -- 32.20 16.04
EPS (TTM): -- -- --
ROI: -- 15.06 34.69
ROE: -- 16.55 15.46

BRIEF-Jiangsu Hengrui Medicine passes U.S. FDA approval

* Says it received FDA approval for Dexmedetomidine Hydrochloride Injection from U.S. Food and Drug Administration

Nov 29 2017

BRIEF-Jiangsu Hengrui Medicine gets approval for clinical trials of drugs

* Says it gets clinical trials approval for its drug named Seebri® Breezhaler® from China Food and Drug Administration

Nov 07 2017

BRIEF-Jiangsu Hengrui Medicine's 9-month net profit up 20.7 pct y/y

* Says 9-month net profit up 20.7 percent y/y at 2.3 billion yuan ($347.33 million)

Oct 18 2017

BRIEF-Jiangsu Hengrui Medicine passes FDA approval

* Says it received approval for its cisatracurium besilate injection from U.S Food and Drug Administration

Sep 05 2017

BRIEF-Jiangsu Hengrui Medicine's H1 net profit up 19.7 pct y/y

* Says H1 net profit up 19.7 percent y/y at 1.6 billion yuan ($242.26 million)

Aug 29 2017

BRIEF-Jiangsu Hengrui Medicine and unit plans clinical trail for new drug SHR0302

* Says it and unit plans to start clinical trail for new drug SHR0302, which is a kind of selective depressant used for treatment of rheumatoid arthritis

Aug 15 2017

BRIEF-Jiangsu Hengrui Medicine passes U.S. FDA approval

* Says it received FDA approval for Docetaxel Injection from U.S Food and Drug Administration

Aug 15 2017

BRIEF-Jiangsu Hengrui Medicine's main product enters into National health insurance's list

* Says its main product ApatinibMesylate Tablets, a oral absorption, has been listed on National health insurance's list

Jul 21 2017

Earnings vs. Estimates